Q1 2021 Eisai Co Ltd Earnings Call Transcript
Thank you this is Yanagi, CFO, speaking about financial part. Please look at Page 2. Here, you see the consolidated statement of income or P&L for the first quarter. Based on our Partnership model, we have overcome the impact by COVID-19. We have exceeded plan and achieved increase in both revenue and profit. Top line revenue was JPY 165.6 billion, up 8% from a year earlier. There were impacts of COVID-19, drug price revision in Japan and foreign exchange rates, which was partly offset by royalty for tazemetostat and core growth driver, LENVIMA, increased revenue by JPY 10 billion, leading to 8% increase in revenue from a year earlier.
LENVIMA profitability is very high. That is to say, cost ratio is very low. And together with the business development projects, cost ratio has been reduced to 23.1%.
Gross profit was JPY 127.3 billion, up 15% from a year earlier, with double-digit growth. And this total expenses increase was contained within the increase in the gross profit, therefore, leading to a significant increase in profit
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
